Odylia delivers on the promise of treatments for the vastly underserved rare disease patient community. By pivoting to a nonprofit drug development model and away from the economic barriers and unaligned incentives of the traditional model, Odylia increases drug development while accelerating timelines and reducing costs.
Odylia Therapeutics is a nonprofit biotech developing therapies for rare diseases that have no available treatment. By integrating scientific knowledge, operational excellence, and technological innovation, Odylia offers hope and improved health, impacting current and future generations. Odylia’s focus starts and ends with patients.
Follow the link below to learn more about Odylia’s gene therapy pipeline and how we partner with Patient Groups to empower their drug development efforts.
With little commercial interest in treatments for rare disease, Odylia relies on contributions from individuals, other nonprofit organizations, patient groups, and corporate donors to bring life-changing treatments to patients. Learn more about how you can make a difference.